The Gores Group Completes the Acquisition of Therakos, Inc. from Ortho-Clinical Diagnostics, Inc.

  The Gores Group Completes the Acquisition of Therakos, Inc. from
  Ortho-Clinical Diagnostics, Inc.

Business Wire

LOS ANGELES -- January 2, 2013

The Gores Group, a global investment firm focused on acquiring controlling
interests in mature and growing businesses, today announced that it has
completed the acquisition of Therakos, Inc. from Ortho-Clinical Diagnostics,
Inc. Terms of the transaction were not disclosed.

Therakos, based in Raritan, New Jersey, is a global leader in advanced
technologies for extracorporeal photopheresis. THERAKOS® Photopheresis Systems
are the only integrated systems for extracorporeal photopheresis, a
leukapheresis-based immunomodulatory therapy that has been approved by the
U.S. Food and Drug Administration for the palliative treatment of the skin
manifestations of cutaneous T-cell lymphoma unresponsive to other forms of
treatment. The unique system has a demonstrated track record of efficacy and
safety and has been used globally for more than 25 years.

Michael Rechtiene, the newly appointed CEO of Therakos, stated, “Therakos has
been a pioneer in bringing generations of photopheresis therapy to patients
around the world. The new generation THERAKOS™ CELLEX® Photopheresis System
incorporates innovative and advanced technologies, providing a new level of
care that can also significantly reduce treatment times.”

“Therakos’ leadership position and history of innovation puts Therakos in a
great position to continue to meet and exceed the expectations of our
customers as an independent company,” stated Edward Johnson, Managing Director
of The Gores Group. “Therakos is another vital step in Gores’ expansion into
the healthcare industry and we are excited for this opportunity.”

About The Gores Group

The Gores Group, LLC is a global investment firm focused on acquiring
controlling interests in mature and growing businesses which can benefit from
the firm's operating experience and flexible capital base. The firm combines
the operational expertise and detailed due diligence capabilities of a
strategic buyer with the seasoned M&A team of a traditional financial buyer.
The Gores Group, which was founded in 1987 by Alec E. Gores, has become a
leading investor having demonstrated over time a reliable track record of
creating substantial value in its portfolio companies alongside management.
Headquartered in Los Angeles, The Gores Group maintains offices in Boulder,
CO, and London. For more information, please visit www.gores.com.

Important Safety Information
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate
extracorporeal volume loss or shifts, or patients with coagulation disorders.
See Important Safety Information for additional details.
Methoxsalen Sterile Solution is indicated for extracorporeal administration
with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the
palliative treatment of the skin manifestations of cutaneous T-cell lymphoma
(CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the
THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems.
Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions
to psoralen compounds, patients with a specific history of a light sensitive
disease, or patients with aphakia.
View complete Prescribing Information and Important Safety Information
available at
http://www.therakos.com/healthcare-professionals/photopheresis/clinical-evidence/safety

Contact:

For The Gores Group, LLC
Frank Stefanik
(310) 209-3010
or
Sitrick And Company
Terry Fahn
(310) 788-2850
 
Press spacebar to pause and continue. Press esc to stop.